PathoCare Holdings, Inc. Accepts Third-Party Tender Offer Valuing the Company at $500 Million and Launches New Equity Round to Support Product Development
PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC (a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostics)—has developed a set of tests backed by a revolutionary Raman spectroscopy-based testing platform that is underpinned by 17 patents and adaptive AI. Today, the company announced that it has accepted a third-party tender offer involving the secondary purchase of shares from an early investor. While specific transaction details remain undisclosed, the agreement reflects a company valuation of $500 million.
